Yuan K, Tang Y, Ding Z, Peng L, Zeng J, Wu H
Front Mol Biosci. 2024; 11:1434398.
PMID: 39479502
PMC: 11521912.
DOI: 10.3389/fmolb.2024.1434398.
Wang Y, Ma Q, Chen J, Li S, Zheng F, Shi L
BMC Pediatr. 2024; 24(1):631.
PMID: 39363269
PMC: 11448441.
DOI: 10.1186/s12887-024-05088-0.
Schmidt A, Zhang H, Schmitt S, Rausch C, Popp O, Chen J
Cells. 2024; 13(2).
PMID: 38247831
PMC: 10814525.
DOI: 10.3390/cells13020139.
Bedics G, Szoke P, Batai B, Nagy T, Papp G, Kranitz N
Sci Rep. 2023; 13(1):18436.
PMID: 37891325
PMC: 10611758.
DOI: 10.1038/s41598-023-45786-w.
Salomoni P, Flanagan A, Cottone L
Cell Death Differ. 2023; 32(1):66-77.
PMID: 37828086
PMC: 11748643.
DOI: 10.1038/s41418-023-01227-9.
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Malgulwar P, Danussi C, Dharmaiah S, Johnson W, Singh A, Rai K
Neuro Oncol. 2023; 26(1):55-67.
PMID: 37625115
PMC: 10769000.
DOI: 10.1093/neuonc/noad155.
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer.
Pang Y, Chen X, Ji T, Cheng M, Wang R, Zhang C
Cancers (Basel). 2023; 15(8).
PMID: 37190157
PMC: 10136513.
DOI: 10.3390/cancers15082228.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T
Cancer Discov. 2023; 13(7):1556-1571.
PMID: 37068173
PMC: 11024958.
DOI: 10.1158/2159-8290.CD-22-1420.
Molecular Basis and Genetic Modifiers of Thalassemia.
Tesio N, Bauer D
Hematol Oncol Clin North Am. 2023; 37(2):273-299.
PMID: 36907603
PMC: 10122828.
DOI: 10.1016/j.hoc.2022.12.001.
Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.
DeWitt S, Hoskinson Plumlee S, Brighton H, Sivaraj D, Martz E, Zand M
JCI Insight. 2022; 7(17).
PMID: 36073547
PMC: 9536280.
DOI: 10.1172/jci.insight.151583.
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
de Nonneville A, Salas S, Bertucci F, Sobinoff A, Adelaide J, Guille A
EMBO Mol Med. 2022; 14(10):e15859.
PMID: 35920001
PMC: 9549729.
DOI: 10.15252/emmm.202215859.
The chromatin remodeller ATRX facilitates diverse nuclear processes, in a stochastic manner, in both heterochromatin and euchromatin.
Truch J, Downes D, Scott C, Gur E, Telenius J, Repapi E
Nat Commun. 2022; 13(1):3485.
PMID: 35710802
PMC: 9203812.
DOI: 10.1038/s41467-022-31194-7.
Dataset of differentially expressed genes in mouse P12 testes in response to the loss of ATRX in Sertoli cells.
Bagheri-Fam S, Alankarage D, Frost E, Harley V
Data Brief. 2022; 42:108230.
PMID: 35592768
PMC: 9111927.
DOI: 10.1016/j.dib.2022.108230.
Cellular senescence in neuroblastoma.
Zanotti S, Decaesteker B, Vanhauwaert S, De Wilde B, De Vos W, Speleman F
Br J Cancer. 2022; 126(11):1529-1538.
PMID: 35197583
PMC: 9130206.
DOI: 10.1038/s41416-022-01755-0.
Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis.
Wen T, Chen Q
Front Oncol. 2022; 11:806974.
PMID: 35087762
PMC: 8786718.
DOI: 10.3389/fonc.2021.806974.
Telomeres and Cancer.
Fan H, Chang F, Tsai J, Lin K, Chen C, Lin S
Life (Basel). 2021; 11(12).
PMID: 34947936
PMC: 8704776.
DOI: 10.3390/life11121405.
Alternative Lengthening of Telomeres: Lessons to Be Learned from Telomeric DNA Double-Strand Break Repair.
Kent T, Clynes D
Genes (Basel). 2021; 12(11).
PMID: 34828344
PMC: 8619803.
DOI: 10.3390/genes12111734.
Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis.
Forsyth R, Krenacs T, Athanasou N, Hogendoorn P
Cancers (Basel). 2021; 13(20).
PMID: 34680268
PMC: 8534144.
DOI: 10.3390/cancers13205119.
PML-NB-dependent type I interferon memory results in a restricted form of HSV latency.
Suzich J, Cuddy S, Baidas H, Dochnal S, Ke E, Schinlever A
EMBO Rep. 2021; 22(9):e52547.
PMID: 34197022
PMC: 8419685.
DOI: 10.15252/embr.202152547.
The Multiple Facets of ATRX Protein.
Valenzuela M, Amato R, Sgura A, Antoccia A, Berardinelli F
Cancers (Basel). 2021; 13(9).
PMID: 34062956
PMC: 8124985.
DOI: 10.3390/cancers13092211.